TABLE 1.

Origins and antifungal susceptibilities of atypical isolates

PatientIsolateYraPrior therapybSite of isolationcMIC/MFCd (μg/ml)MEC of CAS (μg/ml)
ITZVRZAMB
1W11995FLU, AMBLung0.5/12/42/416
W21995FLU, AMBKidney1/22/41/24
2W31998FLUMouth1/22/42/216
W41998FLULung1/22/41/2>32
3W51999FLULung1/22/22/416
4W62000AMB, VRZLung1/22/41/432
W72000AMB, VRZMouth1/22/42/432
  • a Year during which isolates were recovered from the indicated site.

  • b Antifungal therapy prior to day of infection.

  • c Isolates recovered from either bronchoalveolar lavage or lung biopsy specimens are indicated as “lung.” Kidney isolates were recovered at autopsy.

  • d MICs shown were determined by the NCCLS method, as described in Materials and Methods.